Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Jochen Greiner, MD, Vanessa Schneider, Dr. rer. nat., Hubert Schrezenmeier, Markus Wiesneth, MD, Susanne Hofmann, MD, Marlies Götz

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-134876

Published: 2020

Journal Articles

Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases

Susanne Hofmann, MD, Marlies Götz, Cornelia Herbst, Vanessa Schneider, Markus Wiesneth, MD, Donald Bunjes, MD, Hartmut Döhner, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 2442.

https://doi.org/10.1182/blood.V124.21.2442.2442

Published: 2014

Journal Articles

Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013)

Susanne Hofmann, MD, Lisa Müller, Stephanie Harsdorf, MD, Christian Langer, MD, Peter Liebisch, MD, Jochen Greiner, MD, Hartmut Döhner, MD, Donald Bunjes, MD

Blood (2014) 124 (21): 1233.

https://doi.org/10.1182/blood.V124.21.1233.1233

Published: 2014

Journal Articles

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Vanessa Schneider, Lu Zhang, Markus Rojewski, Lars Bullinger, MD PhD, Susanne Hofmann, MD, Marlies Goetz, Konstanze Doehner, MD, Hartmut Doehner, Prof., Christian Buske, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 5783.

https://doi.org/10.1182/blood.V124.21.5783.5783

Published: 2014

Journal Articles

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Vanessa Schneider, Lars Bullinger, MD, PhD, Lu Zhang, Markus Rojewski, Markus Wiesneth, Susanne Hofmann, Marlies Goetz, Hubert Schrezenmeier, MD, Ulla Botzenhardt, Thomas F.E. Barth, Konstanze Doehner, MD, Hartmut Doehner, MD, Jochen Greiner, MD

Blood (2013) 122 (21): 2624.

https://doi.org/10.1182/blood.V122.21.2624.2624

Published: 2013

Journal Articles

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Susanne Hofmann, Vanessa Schneider, Lars Bullinger, Yoko Ono, Anita Schmitt, Lu Zhang, Marlies Götz, Konstanze Döhner, MD, Ph.D, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, Jochen Greiner, MD

Blood (2012) 120 (21): 3592.

https://doi.org/10.1182/blood.V120.21.3592.3592

Published: 2012

Journal Articles

Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia

Lu Zhang, Susanne Hofmann, Lars Bullinger, Marlies Goetz, Markus Wiesneth, Markus Rojewski, Hartmut Dohner, MD, Jochen Greiner, MD, Vanessa Schneider

Blood (2011) 118 (21): 4997.

https://doi.org/10.1182/blood.V118.21.4997.4997

Published: 2011

Journal Articles

Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial

Katja Sockel, MD, Jochen Greiner, MD, Rudolf Trenschel, MD, Christian Unzicker, MD, Guido Kobbe, MD, Jürgen Finke, MD, Ulrich Germing, MD, Brigitte Mohr, Dietrich Beelen, Gerhard Ehninger, MD, Martin Bornhaeuser, Uwe Platzbecker, MD

Blood (2011) 118 (21): 3060.

https://doi.org/10.1182/blood.V118.21.3060.3060

Published: 2011

Journal Articles

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Jochen Greiner, MD, Yoko Ono, Susanne Hofmann, Vanessa Schneider, Anita Schmitt, Lu Zhang, Elmar Mehring, Marlies Götz, Konstanze Döhner, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, MD, PhD

Blood (2011) 118 (21): 2569.

https://doi.org/10.1182/blood.V118.21.2569.2569

Published: 2011

Journal Articles

Preemptive Donor Lymphocyte Infusion Induces Polyspecific T-Cell Responses in a Patient with AML with NPM1 Mutation

Susanne Hofmann, Marlies Götz, Cornelia Herbst, Vanessa Schneider, Lu Zhang, Donald Bunjes, MD, Hartmut Döhner, MD, Markus Wiesneth, Jochen Greiner, MD

Blood (2011) 118 (21): 4311.

https://doi.org/10.1182/blood.V118.21.4311.4311

Published: 2011

Journal Articles

Expression of RHAMM and WT1 As Well As T Cell Responses to These Antigens Before and After Allogeneic Stem Cell Transplantation in Patients with Leukemia

Rosaely Casalegno-Garduño, Claudia Meier, Jiju Mani, Kersten Borchert, Inken Hilgendorf, Yvonne Gross, Anna Filipowska, Dirk Koczan, Alf Spitschak, Michael Linnebacher, Anita Schmitt, Jochen Greiner, MD, Mathias Freund, Brigitte M Püutzer, Michael Schmitt

Blood (2011) 118 (21): 4315.

https://doi.org/10.1182/blood.V118.21.4315.4315

Published: 2011

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Krzysztof Giannopoulos, MD, PhD, Andreas Buhler, MD, PhD, Jinfei Chen, MD, PhD, Alexander Krober, MD, PhD, Malgorzata Kowal, MD, PhD, Anna Dmoszynska, MD, PhD, Jacek Rolinski, MD, PhD, Jochen Greiner, MD, PhD, Hartmut Dohner, MD, PhD, Stephan Stilgenbauer, MD, PhD, Michael Schmitt, MD, PhD

Blood (2007) 110 (11): 2051.

https://doi.org/10.1182/blood.V110.11.2051.2051

Published: 2007

Journal Articles

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Jochen Greiner, MD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Jinfei Chen, MD, Marlies Goetz, Markus Rojewski, MD, Gerd Ritter, PhD, Sascha Gnjatic, PhD, Philippe Guillaume, PhD, Mark Ringhoffer, MD, Martin Bommer, MD, Richard F. Schlenk, MD, Peter Liebisch, MD, Donald Bunjes, MD, Hiroshi Shiku, PhD, Hartmut Dohner, MD, Michael Schmitt, MD

Blood (2007) 110 (11): 1806.

https://doi.org/10.1182/blood.V110.11.1806.1806

Published: 2007

Journal Articles

Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.

Jochen Greiner, MD, Jan Torzewski, MD, Peter Ponsaerts, PhD, Markus T. Rojewski, PhD, Desiree Kronawitter, PhD, Hubert Schrezenmeier, MD, Vinzenz Hombach, MD, Hartmut Dohner, MD, Michael Schmitt, PhD, Markus Wiesneth, MD, Oliver Zimmermann, MD, Juliane M. Wiehe, PhD

Blood (2006) 108 (11): 5471.

https://doi.org/10.1182/blood.V108.11.5471.5471

Published: 2006

Journal Articles

Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.

Jochen Greiner, MD, Michael Schmitt, PhD, Li Li, PhD, Krzysztof Giannopoulos, MD, Katrin Bosch, Konstanze Dohner, MD, Anita Schmitt, MD, Richard F. Schlenk, MD, Jonathan R. Pollack, PhD, Hartmut Dohner, MD, Lars Bullinger, MD

Blood (2006) 108 (11): 414.

https://doi.org/10.1182/blood.V108.11.414.414

Published: 2006

Journal Articles

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Jinfei Chen, MD, Anita Schmitt, MD, Baoan Chen, MD, Markus Rojewski, MD, Jochen Greiner, MD, Philippe Guillaume, PhD, Hartmut Dohner, MD, Donald Bunjes, MD, Michael Schmitt, PhD

Blood (2006) 108 (11): 2201.

https://doi.org/10.1182/blood.V108.11.2201.2201

Published: 2006

Journal Articles

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Jochen Greiner, MD, Krzysztof Giannopoulos, MD, Li Li, MD, Peter Liebisch, MD, Christiane Wendl, MD, Jinfei Chen, MD, Mark Ringhoffer, MD, Phillipe Guillaume, PhD, Gerd Ritter, PhD, Hartmut Doehner, MD, Michael Schmitt, MD

Blood (2005) 106 (11): 2781.

https://doi.org/10.1182/blood.V106.11.2781.2781

Published: 2005

Journal Articles

Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules.

Jochen Greiner, MD, Li Li, MD, Krzysztof Giannopoulos, MD, Christian Brunner, Konstanze Döhner, MD, Hartmut Döhner, MD, Michael Schmitt, MD

Blood (2005) 106 (11): 2886.

https://doi.org/10.1182/blood.V106.11.2886.2886

Published: 2005

Journal Articles

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.

Krzysztof Giannopoulos, MD, Iwona Hus, PhD, Li Li, MD, Agnieszka Bojarska-Junak, PhD, Jochen Greiner, MD, Jacek Rolinski, PhD, Anna Dmoszynska, PhD, Hartmut Doehner, MD, Michael Schmitt, MD

Blood (2005) 106 (11): 53.

https://doi.org/10.1182/blood.V106.11.53.53

Published: 2005

Journal Articles

Characterization of T Cell Epitopes of the Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) in Acute Myeloid Leukemia.

Michael Schmitt, MDPhD, Li Li, PhD, Mark Ringhoffer, MD, Thomas Barth, MD, Markus Wiesneth, MD, Hartmut Dohner, MDPhD, Jochen Greiner, MD

Blood (2004) 104 (11): 2540.

https://doi.org/10.1182/blood.V104.11.2540.2540

Published: 2004

NARROW

Frequency and Stimulation of NPM1-Specific Immune Responses By Anti-PD1 Antibodies in NPM1-Mutated AML

Cytotoxic T-Cell Responses (CTL) Against Several Leukemia-Associated-Antigens (LAA) Related to the Detected Cytokine Profile in the Course of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Donor Lymphocyte Infusion (DLI) in Patients with Different Hematological Diseases

Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013)

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia

Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial

The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses

Preemptive Donor Lymphocyte Infusion Induces Polyspecific T-Cell Responses in a Patient with AML with NPM1 Mutation

Expression of RHAMM and WT1 As Well As T Cell Responses to These Antigens Before and After Allogeneic Stem Cell Transplantation in Patients with Leukemia

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.

Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules.

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.

Characterization of T Cell Epitopes of the Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only